The future of personalized cancer treatment: An entirely new direction for RNAi delivery
In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells. The work will be ...
Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
HUNTSVILLE, Ala., April 15 /PRNewswire/ -- Open Biosystems, Inc.,
focused on the commercialization of leading-edge life science research
tools for drug discovery, today announced the availability of new
viral screening pools for multiplexed RNAi
novel offering all...
Cellectricon Launches World's First System for High Throughput RNAi Screening
GOTHENBERG, Sweden, March 27 /PRNewswire/ -- Cellectricon, a leading
provider of screening solutions for drug discovery, today announced the
launch of the new Cellaxess(R)HT System. The world's first fully automated
high throughput transfection system enables reagent-free delivery of
Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide
University College London and Hospital for Sick Kids purchase Open Access to lentiviral RNAi
HUNTSVILLE, Ala., March 26 /PRNewswire/ -- Open Biosystems, Inc.,
announced today that two leading research institutions, University College
London (UCL), U.K., and the Ho...
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced
electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01
in a Phase I human clinical trial. Results of the Phase I trial were
announced today at the 18th Annual Drug Delivery to the Lungs meeting held
Patent for Seminal RNAi innovation Cleared in Australia
Opposition in Australia to the grant of patent application to the Carnegie Institution of Washington in relation to the discovery of RNAi
has been withdrawn.// This was announced by the Carnegie Institution of Washington and the University of Massachusetts Medical School. The opposition was origina...
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
...rence represent Quark's leadership position in the rnai
industry as the pioneer in systemic siRNA administ...target identification to drug development. Quark's rnai
technology includes novel siRNA structures and che...ts to utilize the structures to develop additional rnai
Quark is headquartered in ...
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
... to the clinic. Our leadership position within the rnai
field is set to continue with the upcoming IND fil...target identification to drug development. Quark's rnai
technology includes novel siRNA structures and che...d is utilizing the chemistry to develop additional rnai
drug candidates. QPI-1007 is the most advanced and...
Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
...based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's rnai
technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as ...
Cancer cells need normal, nonmutated genes to survive
... (In the past, labs relied on large robots to complete these types of screens, but Elledge and others have refined the technology in an effort to make rnai
affordable and accessible. Luo conducted his genome-wide screen in test tubes without the aid of a robot.)
Despite their similarities, the two cell...
RNAi in Medical Technology
Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally a...
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Data Validates Neuroprotective Effect of Quark's New RNAi
Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc.,
a development-stage pharmaceutical company discovering and developing novel
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Clinical Program Leverages Quark's RNAi
FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
development-stage pharmaceutical company discovering and developing novel
RNA interference (RNAi)-based therapeutics, today announced that its
partner, Pfizer Inc, initi...
Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Cequent Pharmaceuticals, a
pioneer in the development of novel products to deliver RNAi-based
treatments to prevent and treat human disease, announced that its Vice
President of Research, Johannes Fruehauf, MD, Ph.D., is slated to speak at
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow
platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II
human clinical trial that has begun enrolling patients. ALN-RSV01 is a RNAi
therapeutic being developed as a treatment for respiratory syncytial virus
Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
Findings Support Gene-Silencing Mechanism and Demonstrate Significant Tumor Growth Inhibition Across Multiple Tumor Models in Mice
PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a
leading developer of targeted, systemic RNA interference (RNAi)
therapeutics, today anno...
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an
RNA interference (RNAi)-based therapeutics developer, announced today that
it has entered into a collaboration and license agreement with Pfizer Inc.
to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033...
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Quark's Novel siRNA Structures Exhibit Stability and Activity in vitro
FREMONT, Calif., Aug. 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
clinical-stage biopharmaceutical company focused on discovering and
developing novel RNA interference-based therapeutics, announced today that
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA
FREMONT, Calif., Aug. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
clinical-stage biopharmaceutical company focused on discovering and
developing novel RNA inte...
Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect
with Lead RNAi Candidate
PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Calando
Pharmaceuticals, a leading siRNA therapeutics company and a
majority-owned subsidiary of Arrowhead Research Corporation
(NASDAQ:ARWR) announced the publication of a study demonstrating
the anti-proliferative effect of the siRNA sequence selec...
RNAi in Medical Products
QuantiGene 2.0 RNA Quantification System
Features:...om crude cell lysates to eliminate amplification bias
Branched DNA technology enhances assay sensitivity to detect low expressing genes
assays by accurate amplification of target sequences
RNAi in Biological News
Cold Spring Harbor Protocols features stem cell differentiation, plant RNAi methods
COLD SPRING HARBOR, N.Y. (Mon., Feb. 2, 2009) -- By using OP9-DL1 cells as a support system, researchers can study the differentiation of embryonic stem cells into mature components of the immune system. This month's issue of Cold Spring Harbor Protocols ( www.cshprotocols.org/TOCs/toc2_09.d...
UMMS and CIW grant key RNAi rights to Oxford Biomedica
WORCESTER, MA, AND WASHINGTON, DCThe University of Massachusetts Medical School and the Carnegie Institution of Washington announced today that they have entered into licensing agreements with Oxford BioMedica (LSE: OXB), a gene therapy company, that grants the company rights to key RNA interfere...
For Stanford scientists, RNAi gene therapy takes two steps forward, one step back
Three years ago Mark Kay, MD, PhD, published the first results showing that a hot new biological phenomenon called RNA interference was an effective gene-therapy technique in mice. That finding kicked off an RNAi
gene therapy research flurry amongst both academic and industry research groups.
New RNAi tools enable systematic studies of gene function
An international public-private research team led by scientists at the Broad Institute of MIT and Harvard announced today the construction and availability of an extensive library of molecular reagents to silence most human and mouse genes.
As described in the March 24 issue of Cell, this library...
Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance
When it comes to the deadly skin cancer melanoma, studying functional tissue rather than cell lines may better provide insight into the disease's development, according to new research from a Howard Hughes Medical Institute predoctoral fellow at Stanford University School of Medicine.
The downside of microtubule stability
were abnormally stable, as measured by how many acetyl groups were attached to them. The researchers also found that blocking normal dynamin 2 with rnai
had the same effect as the mutation, confirming that one of dynamin 2's functions is to promote microtubule turnover.
Removing dynamin 2 shattered ...
Recruitment of reproductive features into other cell types may underlie extended lifespan in animals
...to enhanced immune response including increased control of gene expression through RNA interference (RNAi) in somatic cells. Since it is known that rnai
is among the mechanisms underlying germline cells' enhanced resistance to pathogens and other stresses, the researchers examined whether the reactivat...
CSHL researchers explain process by which cells 'hide' potentially dangerous DNA segments
...ves a host of players: the enzyme that copies DNA into RNA, which is diced into short segments called short interfering RNAs, or siRNAs; a part of the rnai
machinery known as the RITS complex; and various enzymes that are able to alter the configuration of chromatin.
A debate over recruitment
A new gene silencing platform -- silence is golden
...m with very significant improvements over existing rnai
approaches. This may enable the development and di...sibly inhibit genes that do not respond to current rnai
The applications of U1 Adaptors expand on those currently available using standard rnai
approaches. They can be used as a research tool to...
International public-private partnership offers new paradigm for medicinal chemistry
...vity of a protein, specifically designed to affect the activity of proteins involved in epigenetic control. They will complement genetic knockouts and rnai
approaches to understand the role of these proteins in biology. The probes need to be highly selective for their target protein, and suitable for use ...
RNAi in Biological Technology
Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening
ST. LOUIS, April 28 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL ) today announced the global release of MISSION(R) esiRNA, a pool of gene-specific siRNA that provides a novel and powerful approach to RNAi
screening in mammalian cells. Unlike traditional synthetic RNAi, esiRNA ( htt...
Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC
(OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the
development of technologies that target the science of healthy aging, today
announced an agreement with the Institute of Bioorganic Chemistry of the
Polish Academy of Sci...
Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading
developer of targeted, systemic RNA interference (RNAi) therapeutics, today
announced the issuance of United States patent 7,459,547, entitled "Methods
and Compositions for Controlling Efficacy of RNA Silencing." The issue...
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )
announced today the global release of MISSION(R) In VIVO QUALITY and iScale
Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are
expected to allow researchers to successfully take the next step in ...
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System
GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading
provider of advanced screening solutions for drug discovery, has today
received its most significant and largest single order to date. The order
includes three Cellaxess(R)HT systems and the customer is a leading US
Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
Researchers gain access to Sigma-Aldrich's leading MISSION(TM) shRNA libraries
ST. LOUIS, Oct. 15 /PRNewswire/ -- Sigma-Aldrich (Nasdaq: SIAL ), a
leading life science company and member of The RNAi
proudly welcomes the Memorial Sloan-Ketterin...
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
FREMONT, Calif., Sept. 17 /PRNewswire/ -- Quark Pharmaceuticals, Inc.,
a development-stage pharmaceutical company discovering and developing novel
RNA interference (RNAi)-based therapeutics, today announced the
presentation of posters at the 5th Annual RNAi
Europe, taking place
Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
U.S. AtuRNAi Patent Allowance Builds on European Equivalent Granted in 2007, Expanding Commercial Protection
LONDON, July 31 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a
leading European RNAi
focused biotechnology company, today announced that
the United States Paten...
Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
Sigma-Aldrich to Provide Full Functional Validation Data for Its MISSION(R) shRNA Collection
ST. LOUIS, May 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq:
SIAL) and the second phase of The RNAi
Consortium (TRC2) have commenced
functional validation of the Conso...
febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
RNA, microRNA Researchers Comprise One of the Main User Groups of febit's Simplified and Automated Microarray Technology
MEDFORD, Mass., and HEIDELBERG, Germany, April 22 /PRNewswire/ -- febit
holding gmbh today announced it will introduce the Geniom RT Analyzer(R) to
the U.S. marke...
RNAi in Biological Products
csiRNA By Request
1500 RNAi Reactions from Panomics
MEGAscript RNAi Kit from Ambion
Description: The MEGAscript RNAi
Kit is optimized for the synthesis of large mass amounts of ready-to-use dsRNA for RNAi
experiments in non-mammalian systems. The MEGAscript RNAi
Kit is based on Ambions patented high-yield transcription technol-ogy and includes reagents for transcription, nuclease digestion and...
BLOCK-iT Adenoviral RNAi Expression System from Invitrogen
Complete RNAi from OligoEngine
Description: Since OligoEngine introduced the industry's first siRNA sequence design software in 2001, we have constantly strived to keep these tools consistent with new experimental strategies and published research reports in the field of RNAi. With the introduction of our new, enhanced, and expanded RNAi
siSolutions RNAi Services from B-Bridge International
Description: B-Bridge's siSolutions RNAi
Services offer you a full range of solutions for your siRNA studies. B-Bridges advanced design parameters, effective synthetic siRNA reagents, and technical expertise ensure that you obtain quality results from your siRNA experiments. siSolutions siRNA Design Service uti...
ENGENISTM siRNA Test System from Yorkshire Bioscience Ltd
Description:...itative approach for evaluation of a potential of any DNA sequence to serve as an efficient target for RNA interference (RNAi). Current computer-based rnai
target searching algorithms are not perfect, leaving the probability of selected sequence to be a good target from 30% to 60%. It is therefore clear t...
Company:Yorkshire Bioscience Ltd
HP GenomeWide siRNA from QIAGEN
Genomewide, predesigned siRNAs for a direct route to successful rnai
Ready-to-use, convenient matching solutions for SYBR Green based quantitative RT-PCR Cost-effective rnai
and downstream analysis
Convenient online ordering at GeneGlobe ...
RNAi in Biological Definition
In the yeast Schizosaccharomyces pombe (and likely in other eukaryotes) the formation of centromeric heterochromatin is connected to rnai
* . In nematodes such as Caenorhabditis elegans and in some plants, chromosomes are "holocentric" indicating that there is not a primary site of mic...
...echnique is the application of RNA interference . rnai
creates a specific knockout effect without actually mutating the DNA of interest. In C. elegans , rnai
has been used to systematically interfere with the...ockdown is Morpholino antisense oligos. While rnai
acts by directing cellular systems to degrade targ...
RNAi in Biological Dictionary
RNA interference ( RNAi
) is a system within living cells that helps to control which genes are active and how active they are. Two types of small RNA molecules – microRNA (miRNA) and small interfering RNA (siRNA) – are central... RNAi
.net - News, posters, events and suppliers from the mai...
...taining ... Transgenic - Definition of Transgenic at Dictionary.com a free online dictionary ... Tailored transgenic mouse. Knockout/knockin, rnai
mouse models Contact us ... Transgenic Organism, any microorganism, plant, or animal that has been genetically altered to contain a gene fr...
... ... Altogen Contract Services offer stable cell line generation and rnai
cell ... Transfection Resource: rnai
applications, stable and transient transfection , ... Stable trans...
...designed to reduce off-target effects and increase rnai
performance. Custom siRNA synthesis services and...on reagents. - - Online guide for performing rnai
experiments using synthetic siRNA molecules. ......rhang. ... Home > Products and Services > rnai
Home > Genome-Wide HPLC-Purified siRNA ... Ea...
...erference : A Nature Reviews journals web focus on rnai
- a selection of recently published Reviews, Per...ng RNA Interference's are available. ReadyGene rnai
Kits ... Review of the RNA interference (RNAi) knowledge: rnai
is a post-transcriptional ... Specific interferen...
...anscripts were present at significantly lower ... Figure 1. Key polymerase activities of the RNA World and known organisms. ... Structure of an rnai
Polymerase Links RNA Silencing and Transcription by Paula ... ...
...rs, Electronics, Software and More! Read Recombinant Reviews. Over 30000 antibody/antibodies, 16000 Recombinant Protein/Proteins, 15000 Chimera rnai
and more... Recombinant Protein. Immunohistochemistry. IHC. Assay ... The discovery of recombinant DNA was considered the "birth" of modern bio...
...Talking Computers by Small Press Bookwatch ... Stealth RNAi™ siRNA - in vivo -ready duplexes ... Click for a sortable compilation of in vivo rnai
references. Last updated August 2008. ... Watch Video about In , Vivo ,Tu by Metacafe.com ... In Vivo Tu Tu TU 2007 Www.FolkoTeka.com Spot Dom...
... is a technology that permits one to inactivate genes in ... He's the principal inventor of Benitec's gene silencing technology. ... Article : rnai
Gene Silencing Applications Advance Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business. The Leading Publication i...
... For Low Income Families . Healthy Families . Retinoblastoma Gene . Human Resources Jobs ... Gene Expression. Everything you need to know about rnai
and gene ... Cytokines & Cells Online Pathfinder Encyclopaedia ... When talking about gene families one often encounters the terms homolo...